Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for ImmunityBio (IBRX) over the last 7 years, with Q3 2025 value amounting to $32.0 million.

  • ImmunityBio's Receivables - Net rose 66685.03% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.0 million, marking a year-over-year increase of 66685.03%. This contributed to the annual value of $2.4 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that ImmunityBio reported Receivables - Net of $32.0 million as of Q3 2025, which was up 66685.03% from $22.1 million recorded in Q2 2025.
  • ImmunityBio's Receivables - Net's 5-year high stood at $32.0 million during Q3 2025, with a 5-year trough of $1.0 million in Q2 2024.
  • For the 4-year period, ImmunityBio's Receivables - Net averaged around $8.4 million, with its median value being $1.8 million (2022).
  • As far as peak fluctuations go, ImmunityBio's Receivables - Net crashed by 2053.85% in 2024, and later surged by 204191.67% in 2025.
  • Over the past 4 years, ImmunityBio's Receivables - Net (Quarter) stood at $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then skyrocketed by 81.54% to $2.4 million in 2024, then surged by 1256.61% to $32.0 million in 2025.
  • Its Receivables - Net stands at $32.0 million for Q3 2025, versus $22.1 million for Q2 2025 and $17.0 million for Q1 2025.